Summit's ivonescimab shows survival benefit in lung cancer trial
Go back to Summit's ivonescimab shows survival benefit in lung cancer trial| Stratcomm Media, Ltd. (NASDAQ: SMMT) | Delayed: 14.28 +0.53 (3.85%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.75 | 52 Week High | $19.75 | |||
| Open | $13.78 | 52 Week Low | $4.26 | |||
| Day High | $14.40 | P/E | N/A | |||
| Day Low | $13.70 | EPS | $0.00 | |||
| Volume | 7,385,127 | |||||
